PMC10293962_01
SD-OCT images showing the presence and progress of CME following vitrectomy and insertion of Carlevale scleral fixated IOL at 2 months post-op, with a foveal thickness of 500 mum (a) after 2 months of topical treatment and sub-tenon injection of triamcinolone, persistent edema with foveal thickness of 371 mum (b), and at 3 months following urgent removal of the migrated implant in the AC, complete resolution of the edema (c).
cop529790_f01.jpg
PMC10293962_01_cop529790_f01.jpg
F1
Spectral domain optical coherence tomography confirmed the presence of CME with a foveal thickness of 500 mum in the right eye (Fig. 1a). Following a 2-month course of topical treatment with nepafenac 3 mg/mL (Nevanac) once daily and dexamethasone 0.1% (Maxidex) as well as a posterior sub-tenon injection of triamcinolone acetonide (40 mg/mL) (STTA), there was still a persistent CME (Fig. 1b) with foveal thickness of 371 mum. Of note, a reduction of CMO was also surprisingly noticed which eventually completely resolved and remained quiescent at 1-year follow-up (Fig. 1c).
Anterior segment images of the dislocated dexamethasone implant (a), corneal edema and Descemet's folds (b), and complete resolution of the edema at 1 month post implant removal (c).
cop529790_f02.jpg
PMC10293962_01_cop529790_f02.jpg
F2
Eleven days after implantation, the patient complained of blurry vision, and subsequent slit-lamp biomicroscopy revealed migration of the Ozurdex in the anterior chamber (Fig. 2a) with corneal edema and Descemet's membrane folds (Fig. 2b). At 1 month of follow-up, the cornea was clear, with no observed anterior chamber inflammation and BCVA of 20/25 (Fig. 2c).